Literature DB >> 29802999

Genetic variants in PI3K/Akt/mTOR pathway genes contribute to gastric cancer risk.

Yuqiu Ge1, Hanting Liu1, Xiaonan Qiu2, Gaoxiang Ma1, Haixiao Wang3, Mulong Du1, Meilin Wang1, Qinghong Zhao4, Guoquan Tao5, Haiyan Chu6, Zhengdong Zhang7.   

Abstract

PI3K/Akt/mTOR pathway is involved in tumor initiation and progression, including gastric cancer (GC). However, the single nucleotide polymorphisms (SNPs) in this pathway and underlying molecular mechanism remain largely unexplored. A case-control study of 1275 GC patients and 1436 controls was performed to explore the associations of potentially functional SNPs in PI3K/Akt/mTOR pathway genes with the risk of GC. In the logistic regression analyses, one SNP rs7536272 out of the four candidate SNPs showed a significant association with GC risk (additive model: OR = 1.16, 95% CI = 1.03-1.30; co-dominant model: AG vs. AA, OR = 1.30, 95% CI = 1.11-1.53; dominant model: AG/GG vs. AA, OR = 1.28, 95% CI = 1.10-1.49).The luciferase assay indicated that rs7536272 G allele significantly enhanced the transcriptional activity, compared with A allele. Further expression quantitative trait loci (eQTL) analysis showed that GC patients with rs7536272 AG/GG genotypes had remarkably higher PIK3R3 levels than those with AA genotype, suggesting that rs7536272 polymorphism influenced the expression of PIK3R3. Additionally, we observed that GC patients with high expression of PIK3R3 had significant poorer outcome than those with low expression (HR = 1.29, 95% CI = 1.09-1.53). Our result demonstrated that SNP rs7536272, a functional risk variant located in the promoter region of PIK3R3, showed association with increased transcriptional activity and upregulation of PIK3R3 expression, thus involved in GC development.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Gastric cancer; Genetic variation; Molecular epidemiology; PI3K/Akt/mTOR pathway; Susceptibility

Mesh:

Substances:

Year:  2018        PMID: 29802999     DOI: 10.1016/j.gene.2018.05.093

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  7 in total

1.  Association between Gastric Pathology and Hepatitis B Virus Infection in Patients with or without Helicobacter Pylori.

Authors:  Mahmoud Baghbanian; Seyyed Abolfazl Hoseini Mousa; Masoud Doosti; Mansour Moghimi
Journal:  Asian Pac J Cancer Prev       Date:  2019-07-01

2.  Investigating Potential Molecular Mechanisms of Carcinogenesis and Genes as Biomarkers for Prognosis of Gastric Cancer Based on Integrated Bioinformatics Analysis.

Authors:  Yi Zhu; Xiangwei Sun; Ji Lin; Teming Zhang; Xin Liu; Xian Shen
Journal:  Pathol Oncol Res       Date:  2018-11-14       Impact factor: 3.201

3.  VGLL3 is a prognostic biomarker and correlated with clinical pathologic features and immune infiltrates in stomach adenocarcinoma.

Authors:  Lihua Zhang; Longhai Li; Yong Mao; Dong Hua
Journal:  Sci Rep       Date:  2020-01-28       Impact factor: 4.379

4.  MT1G inhibits the growth and epithelial-mesenchymal transition of gastric cancer cells by regulating the PI3K/AKT signaling pathway.

Authors:  Guofeng Xu; Linfeng Fan; Shufeng Zhao; Canhui OuYang
Journal:  Genet Mol Biol       Date:  2022-02-11       Impact factor: 1.771

5.  Circ_0045714/miR-331-3p interaction affects IL-1β-evoked human articular chondrocyte injury through regulating PIK3R3 in a ceRNA regulatory cascade.

Authors:  Ran Ding; Jinsong Zhou; Jianguo Xu; Huajie Lu; Tingting Zhang; Xiong Xiang; Zhen Shi
Journal:  J Orthop Surg Res       Date:  2021-10-14       Impact factor: 2.359

6.  Babao Dan Reverses Multiple-Drug Resistance in Gastric Cancer Cells via Triggering Apoptosis and Autophagy and Inhibiting PI3K/AKT/mTOR Signaling.

Authors:  Jinyan Zhao; Weilan Lan; Jun Peng; Bin Guan; Jie Liu; Min Zhang; Zhixue Zhan; Jiumao Lin
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-09       Impact factor: 2.629

7.  Discovery of novel isoliquiritigenin analogue ISL-17 as a potential anti-gastric cancer agent.

Authors:  Fengchang Huang; Jin Wang; Yi Xu; Yunfei Zhang; Ning Xu; Liang Yin
Journal:  Biosci Rep       Date:  2020-06-26       Impact factor: 3.840

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.